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LEADING ARTICLE 
Anti Phospholipid Syndrome 
E. Housley 
The Royal Infirmary of Edinburgh, Edinburgh, U.K. 
Arterial and venous thromboses occurring in young 
women and, less commonl3~ men without an obvious 
cause, e.g. presence of risk factors for premature 
atherosclerosis or blood dyscrasias, have long been 
known to vascular surgeons. The recognition of 
autoimmune disorders uch as systemic lupus erythe- 
matosus (SLE), seemed to explain many of these 
occurrences on the basis of vasculitis causing throm- 
bosis. However not all such patients had SLE and, 
even in those that did, there seemed to be a subset in 
whom the disease predominantly caused thrombosis, 
rather than the more usual clinical features of arthrop- 
athy and nephropathy. The first clue to the existence of 
the anti phospholipid syndrome as the cause of these 
thromboses was the discovery of the lupus anticoagu- 
lant (LAC) in 1952. 2This was an in vitro coagulation 
inhibitor found in the plasma of patients with SLE, 
hence the name lupus anticoagulant. Paradoxically, 
however, later these patients with lupus anticoagulant 
were shown to be at a high risk of thrombosis rather 
than haemorrhage. 2 Patients with LAC also often had 
a positive Wassermann reaction the so called "bio- 
logical false positive Wassermann "3 suggesting, as the 
Wassermann reaction depends on binding of syphilis 
antibody to phospholipid, an abnormality of phospho- 
lipid in these patients. In 1983 direct measurement of 
an anti phospholipid antibody (APL) was described 
by Harris et al. 4 It seemed that the lupus anticoagulant 
and APL antibody were similar, though not identical 
antibodies to phospholipid and the anti phospholipid 
syndrome (APLS) was recognised, s The presence of 
APL antibody in young patients with arterial and 
venous thrombosis was confirmed in many studies 
over the next decade. 6 It soon became apparent hat 
not all patients with APLS had SLE and that there 
appeared to be a primary form of the syndrome. 7 Also 
the antibody was found, often transiently, in many 
other disease states such as streptococcal infection, 
malignancy, other autoimmune disorders and use of 
certain drugs. The association of presence of antibody 
and thrombosis i  less clear in these situations. 6 
The main features of the APLS are venous and 
arterial thrombosis, particularly cerebral, recurrent 
foetal oss, thrombocytopenia and skin lesions such as 
livedo reticularis. Many other clinical features uch as 
cardiac disease and other neurological disorders have 
also been described. Diagnostic riteria are not com- 
pletely established but the occurrence of two or more 
thrombotic events in association with levels of APL 
antibody several times the normal, on two or more 
occasions over several weeks, may be taken as 
diagnostic s 
The two laboratory tests used in the diagnosis of the 
condition are the demonstration f LAC in the plasma 
and of raised levels of APL. Presence of LAC depends 
on first showing an abnormality, i.e. prolongation, of 
an in vitro phospholipid ependent test of the intrinsic 
coagulation pathwa~ second that the abnormality is 
due to the presence of an inhibitor and third that the 
inhibitor is directed at phospholipid. The activated 
partial thromboplastin time (APTT), kaolin clotting 
time (KCT) or dilute Russell viper venom test 
(DRVVT) can be used first. 6"8 Presence of an inhibitor 
is shown by mixing studies using normal platelet free 
plasma and confirmation that the inhibitor is directed 
against phospholipid can be shown by use of an 
exogenous phospholipid source, e.g. freeze thawed 
platelets, to reverse the abnormality. If the patient is on 
oral anticoagulants, as is often the case when the 
syndrome is first suspected, testing for lupus anticoag- 
ulant is difficult, needing complex laboratory manoeu- 
vres. s Direct demonstration of raised levels of the 
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antibody can be done by an ELISA, 4 and has the 
advantage that it can be used in anticoagulated 
patients. The antibody is usually IgG or, less com- 
monly, IgM. Patients may sometimes be LAC negative 
but have APL antibody. Although the two tests give 
broadly similar results, it has been suggested that 
presence of LAC is associated with a higher risk of 
thrombosis. 9 Finally it is important o do a thrombo- 
philia screen as well as any other thrombotic disorder 
present will markedly increase the risk of thrombosis 
in these patients. 
The mechanism of the thrombosis is not clearly 
understood. Damage to endothelial cells, impairment 
of prostacyclin synthesis and release, effects on fibri- 
nolysis, defects in protein C and S activation and 
activation of platelets have all been suggested. 6 
The management of APLS has not yet been fully 
worked out as, understandably, with this relatively 
recently described condition with variable diagnostic 
criteria and protean clinical manifestations, adequate 
controlled clinical trials are difficult to do and are still 
awaited. However, it is now clear that thrombosis is 
the major pathological event and that anticoagulation 
is the mainstay of management. In acute thrombosis, 
intravenous heparin should be used initially, followed 
by oral anticoagulation with Warfarin. There is evi- 
dence of a higher rate of thrombosis when anti- 
coagulation is discontinued 1° and, in my experience, 
this is of particular importance in the post-operative 
period. With Warfarin, a high level of anticoagulation 
to an INR of 3-4 times the control level seems to be 
indicated. This is, of course, associated with a higher 
risk of ,bleeding and must therefore be balanced 
against the perceived risk of thrombosis in the 
individual patient. Use of lower dose Warfarin, with 
or without the addition of aspirin, seems to be 
associated with a higher risk of thrombosis. 1°
Attempts to suppress antibody formation by steroids, 
azathioprine or cyclophosphamide have produced 
inconclusive results, 6 but it would seem wise, in the 
author's opinion, to use corticosteroids a well if there 
is clear evidence of autoimmune arteritis such as 
active SLE. 
In summar~ the vascular surgeon called upon to 
deal with arterial or venous thrombosis in young 
women should be aware of the strong possibility of 
APLS causing the thrombosis and, if found, be 
aggressive in the use of anticoagulation i manage- 
ment, particularly after surgery and should maintain 
the patient on long-term anticoagulation afterwards. 
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